|
|
|
|
||
Re: Noluck...biopharma companies will have $1.7T in dealmaking firepower next year, analy$1b gets this easy. Cheap, with long term revenue stream with an expandable label. Do they just want CRMD to do the dirty work first and get approved? |
return to message board, top of board |